Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01644968 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01644968: Completed Phase 1 study, sponsored by Providence Health & Services.
NCT01644968 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01644968, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.
Primary Outcome
A dose limiting toxicity is defined as any grade \>=3 hematologic (except lymphopenia) or non-hematologic toxicity (except hypothyroidism or vitiligo) that, in the opinion of the investigator is considered at lease possibly related to the study treatment. If DLT is observed in greater than two patient in any cohort, then the previous cohort will be the maximal tolerated dose.
Interventions
- DRUG Cohort 1 anti-OX40
- DRUG Cohort 2 anti-OX40
- DRUG Cohort 3 anti-OX40
- BIOLOGICAL Tetanus Day 29
- BIOLOGICAL Tetanus Day 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
What the finished NCT01644968 record still lists
NCT01644968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 5 interventions - of which Cohort 1 anti-OX40 is the first listed.
NCT01644968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01644968 about?
NCT01644968 is a clinical study titled "Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer". This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.
What is the current status of trial NCT01644968?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01644968?
The interventions under investigation include: Cohort 1 anti-OX40 (DRUG), Cohort 2 anti-OX40 (DRUG), Cohort 3 anti-OX40 (DRUG), Tetanus Day 29 (BIOLOGICAL), Tetanus Day 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01644968?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01644968's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia